R&D

Pipeline

The hero of the global First-in Class is Hanmi Pharmaceutical.
Hanmi Pharmaceutical is developing in the areas of anti-cancer,
obesity, diabetes, and rare diseases.

All Pipeline

New Drug Development Status

Last updated 2022-01-29

BIO
Research
Area
Project Indication Preclinical Clinical Licensing
Phase 1 Phase 2 Phase 3 Registration
BIO

Rolontis®(eflapegrastim)

Every three weeks administration*Spectrum code: SPI-2012

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Spectrum

Chemotherapy-
induced neutropenia

complete

complete

complete

complete

complete

Spectrum

efpeglenatideLAPSExd4 Analog

Once weekly~monthly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
Diabetes

complete

complete

complete

ongoing

uncompleted

none

efpegsomatropin(LAPShGH)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Growth hormone
deficiency

complete

complete

complete

uncompleted

uncompleted

none

efinopegdutide(LAPSGLP/GCG)(MK-6024)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

NASH

complete

complete

ongoing

uncompleted

uncompleted

MSD

HM15211(LAPSTriple Agonist)

Once weekly administration (Glucagon/GIP/GLP-1)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

NASH

complete

complete

ongoing

uncompleted

uncompleted

none

HM15136(LAPSGlucagon Analog)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Congenital hyperinsulinism

complete

complete

ongoing

uncompleted

uncompleted

none

HM15912(LAPSGLP-2 Analog)

Once monthly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Short bowel syndrome

complete

complete

ongoing

uncompleted

uncompleted

none

HM12460A / HM12470(LAPSInsulin / LAPSInsulin Analog)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Type 1 & 2 Diabetes

complete

complete

uncompleted

uncompleted

uncompleted

none

HM15136(LAPSGlucagon Analog)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Obesity

complete

ongoing

uncompleted

uncompleted

uncompleted

none

HM14220LAPSInsulin Combo

efpeglenatide +LAPSInsulin Analog

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
Type 2 Diabetes

complete

uncompleted

uncompleted

uncompleted

uncompleted

none

HM15450(Long-acting ASB)

Once monthly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Mucopolysaccharidosis

ongoing

uncompleted

uncompleted

uncompleted

uncompleted

none

HM14320(LAPSGlucagon Combo)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Obesity, NASH, Diabetes

ongoing

uncompleted

uncompleted

uncompleted

uncompleted

none

HM12480(LAPSInsulin 148)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Diabetes

ongoing

uncompleted

uncompleted

uncompleted

uncompleted

none

NCE
Research
area
Project Indication Preclinical Clinical Licensing
Phase 1 Phase 2 Phase 3 Registration
NCE

Oraxol®(paclitaxel + encequidar)

Oral paclitaxel

encequidar: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Athenex

Solid tumors
(Breast cancer)

complete

complete

complete

complete

complete

Athenex

Angiosarcoma

complete

ongoing

uncomplete

uncomplete

none

Luminate®(ALG-1001)

Integrin modulator

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Allegro

Diabetic Mascular Edema Pigmentosa

complete

complete

on going

uncompleted

none

Allegro

Retinitis Pigmentosa

complete

ongoing

uncompleted

uncompleted

none

poseltinib(BTK)

Bruton's tyrosine kinase inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
Autoimmune
disease

complete

complete

ongoing

uncompleted

none

none

poziotinib(pan-HER)

pan-HER inhibitor for multi-targeted anti-cancer drug

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Spectrum|Luye

Solid tumors
(breast, lung cancer)

complete

complete

ongoing

uncompleted

none

Spectrum|Luye

Oratecan(irinotecan + encequidar)

Oral irinotecan

encequidar: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Athenex

Solid tumors
(Colorectal cancer)

complete

complete

ongoing

uncompleted

none

Athenex

Oradoxel(docetaxel+encequidar)

Oral docetaxel

encequidar: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Athenex

Solid tumors

complete

complete

ongoing

uncompleted

none

Athenex

FLX475(CCR4)

Selective oral CCR4 antagonists

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

RAPT MSD

Solid tumors, Hematologic cancers

complete

Phase 1 complete

Phase 2 ongoing

uncompleted

none

RAPT MSD

belvarafenib(pan-RAF)

pan-RAF inhibitor

Multi-targeted anti-cancer drug*Genentech code: RG6185

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

Genentech

Solid tumors

complete

Phase 1 ongoing

uncompleted

uncompleted

none

Genentech

HM43239

Myeloid kinome inhibitor such as FLT3(FMS-like tyrosine kinase 3) and SYK(spleen tyrosine kinase)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

APTOSE

Acute myeloid leukemia

complete

Phase 1 ongoing

uncompleted

uncompleted

none

APTOSE

HM97662 (EZH1/2)

Enhancer of zeste homolog 1/2 dual inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Solid tumors, Hematologic cancers

ongoing

uncompleted

uncompleted

uncompleted

none

none

BIO
Beijing Hanmi’s New Drug Pipeline
BIO

BH2950(PD-1/Her2 BsAb)

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Solid tumors

completed

ongoing

uncompleted

uncompleted

none

INNOVENT

PD-L1/4-1BB BsAb

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Solid tumors

ongoing

uncompleted

uncompleted

uncompleted

none

none

PD-L1/CD47 BsAb

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration

none

Solid tumors,
Hematologic cancers

ongoing

uncompleted

uncompleted

uncompleted

none

none

Immuno-oncology BsAb

Undisclosed target

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Registration
Solid tumors / Hematologic cancers

ongoing

uncompleted

uncompleted

uncompleted

none

Phanes